Guardant in the News
Access to Critical Cancer Screening Tools is At Risk
By now, most Americans have likely heard about the federal court ruling out of Texas regarding access to abortion medication. A second healthcare-related case, also out of Texas, has received less attention, but has the potential to likewise impact healthcare choices for millions of Americans.
Can a Blood Test Screen for Colon Cancer? Guardant Health Chief Medical Officer Shares Promising Update
Currently, there’s a huge push in the cancer community to develop blood tests that can screen for different types of the disease. A company called Guardant Health is working on one of these tools, a test called “Shield” that can screen blood for signs of early-stage colon cancer.
EUCOPE launches the European Coalition for Access to Comprehensive Genomic Profiling (ECGP)
EUCOPE, along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP)
Patients Don’t Want Colonoscopies – Let’s Give Them Something Better
The life-saving potential of alternative screening methods for colorectal cancer
Blood tests may spare cancer patients chemo
A blood test which can detect traces of cancer cells could spare thousands of patients unnecessary chemotherapy every year.
Liquid Biopsy: Unlocking New Insights to Help Improve Outcomes for Cancer Patients
What if a simple blood draw taken during a routine visit to the doctor for a check-up or a flu shot could allow us to identify specific cancers at an early stage, when they are the most treatable? What if blood tests could help the cancer care team improve patient care at every step of the patient’s journey—from detection to treatment selection to response and recurrence monitoring?
Achieving Diversity in Clinical Trials: Charting a More Equitable Path for Research
One year ago, President Biden reinstated the Cancer Moonshot to reduce the nation’s cancer burden and shed light on inequities in cancer care, calling on both the public and private sectors to help meet this challenge. One area where industry can take initiative is ensuring research and clinical trials capture a diverse patient population.
